MultiVir is developing novel tumor suppressor immune gene therapy product candidates that employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors.
Our Preclinical Studies
MultiVir is preparing for a clinical trial with its Adenoviral p53 (Ad-p53) tumor suppressor product candidate in combination with Anti-PD-1 immune therapy. The Ad-p53 is expected to deliver the normal p53 tumor suppressor gene to induce anti-tumor immune responses and targets fundamental molecular defects present in multiple types of cancers.
MultiVir is preparing for a clinical trial with its Adenoviral IL24 (Ad-IL24) tumor suppressor product candidate in combination with Anti-PD-1 immune therapy. The Ad-IL24 is expected to deliver the IL24 gene which has dual tumor suppressor activities that stimulate anti-tumor immunity and inhibit cancer promoting genes that block anti-tumor immune responses.